Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E, et al. Profitable remedy discount and intensification for childhood acute lymphoblastic leukemia primarily based on minimal residual illness monitoring: examine ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol. 2016;34:2591–601.
O’Connor D, Enshaei A, Bartram J, Hancock J, Harrison CJ, Hough R, et al. Genotype-specific minimal residual illness interpretation improves stratification in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2018;36:34–43.
O’Connor D, Moorman AV, Wade R, Hancock J, Tan RM, Bartram J, et al. Use of Minimal Residual Illness Evaluation to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia. J Clin Oncol. 2017;35:660–7.
Toft N, Birgens H, Abrahamsson J, Griskevicius L, Hallbook H, Heyman M, et al. Outcomes of NOPHO ALL2008 therapy for sufferers aged 1–45 years with acute lymphoblastic leukemia. Leukemia 2018;32:606–15
Buchmann S, Schrappe M, Baruchel A, Biondi A, Borowitz M, Campbell M, et al. Remission, therapy failure, and relapse in pediatric ALL: a world consensus of the Ponte-di-Legno Consortium. Blood. 2022;139:1785–93.
Taskinen M, Oskarsson T, Levinsen M, Bottai M, Hellebostad M, Jonsson OG, et al. The impact of central nervous system involvement and irradiation in childhood acute lymphoblastic leukemia: classes from the NOPHO ALL-92 and ALL-2000 protocols. Pediatr Blood Most cancers. 2017;64:242–9.
Vora A, Andreano A, Pui CH, Starvation SP, Schrappe M, Moericke A, et al. Affect of cranial radiotherapy on end result in kids with acute lymphoblastic leukemia handled with modern remedy. J Clin Oncol. 2016;34:919.
den Boer ML, Cario G, Moorman AV, Boer JM, de Groot-Kruseman HA, Fiocco M, et al. Outcomes of paediatric sufferers with B-cell acute lymphocytic leukaemia with ABL-class fusion within the pre-tyrosine-kinase inhibitor period: a multicentre, retrospective, cohort examine. Lancet Haematol. 2021;8:e55–e66.
Brady SW, Roberts KG, Gu Z, Shi L, Kilos S, Pei D, et al. The genomic panorama of pediatric acute lymphoblastic leukemia. Nat Genet. 2022;54:1376–89.
Moorman AV, Enshaei A, Schwab C, Wade R, Chilton L, Elliott A, et al. A novel built-in cytogenetic and genomic classification refines danger stratification in pediatric acute lymphoblastic leukemia. Blood. 2014;124:1434–44.
Enshaei A, O’Connor D, Bartram J, Hancock J, Harrison CJ, Hough R, et al. A validated novel steady prognostic index to ship stratified medication in pediatric acute lymphoblastic leukemia. Blood. 2020;135:1438–46.
Moorman AV, Antony G, Wade R, Butler ER, Enshaei A, Harrison CJ, et al. Time to treatment for childhood and younger grownup acute lymphoblastic leukemia is impartial of early danger elements: long-term follow-up of the UKALL2003 trial. J Clin Oncol. 2022;40:4228–39.
Escherich G, Zimmermann M, Janka-Schaub G. Doxorubicin or daunorubicin given upfront in a therapeutic window are equally efficient in kids with newly recognized acute lymphoblastic leukemia. A randomized comparability in trial CoALL 07-03. Pediatr Blood Most cancers. 2013;60:254–7.
Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360:470–80.
Bashton M, Hollis R, Ryan S, Schwab CJ, Moppett J, Harrison CJ, et al. Concordance of copy quantity abnormality detection utilizing SNP arrays and Multiplex Ligation-dependent Probe Amplification (MLPA) in acute lymphoblastic leukaemia. Sci Rep. 2020;10:45.
